All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Diabetes is one of the most serious public health issues worldwide due to its rapidly increasing incidence and tremendous amount of various vascular complications. According to the International Diabetes Federation, in 2015, the 415 million individuals had diabetes, a figure that is estimated to increase to 642 million by 2040 \[[@pone.0205502.ref001]\] Diabetes is a complicated metabolic disease characterized by chronic inflammation \[[@pone.0205502.ref002], [@pone.0205502.ref003]\] that involves genetic and environmental factors. Insulin resistance, the core defect of metabolic diseases, is linked to low-grade inflammation; however, its detailed molecular mechanism remains to be determined. Recent studies have suggested that the gut microbiota play a fundamental role in metabolic disease development by modifying energy homeostasis \[[@pone.0205502.ref004]--[@pone.0205502.ref008]\]. Studies from animal models have shown that alterations in the gut microbiota contribute to the development of metabolic diseases by increasing endotoxemia-induced inflammation \[[@pone.0205502.ref009]\]. Furthermore, Cox et al. demonstrated that altering the intestinal microbiota in early life using low-dose penicillin switched the metabolic phenotype \[[@pone.0205502.ref010]\]. Ridaura et al. demonstrated that the microbiota derived from discordant obese twins affected murine metabolism \[[@pone.0205502.ref011]\].

Despite long being considered an evolutionary vestigial organ, the human appendix has more recently been recognized as an important part of the immune system. Furthermore, the human appendix may function as a "safe house" to preserve and protect commensal bacteria in the gastrointestinal tract via immune-mediated biofilm formation \[[@pone.0205502.ref012]--[@pone.0205502.ref015]\]. Consequently, appendectomy may change the gut microbiota composition and immune function, subsequently promoting the emergence of various inflammatory diseases, including colon cancer, Crohn's disease, and rheumatoid arthritis \[[@pone.0205502.ref016]--[@pone.0205502.ref021]\]. This study aimed to investigate whether appendectomy increases the risk of type 2 diabetes (DM).

**Informed consent statement.** Although written informed consent was not provided by the participants for the use of their medical records in this study, the patient records were de-identified and anonymized prior to the investigation. The work was approved after a full ethical review by the Institutional Review Board (IRB) of the Changhua Christian Hospital (approval number 171210), and the IRB waived the need for consent.

Material and methods {#sec006}
====================

Study population {#sec007}
----------------

We used a one-million-person random sample from people enrolled in the Taiwan National Health Insurance Program (NHIP). Started in 1995, the program includes 99% of the 23-million-plus people who live in Taiwan. This database from the NHIP is managed and established for investigators. With the hospitalization database from the Taiwan NIHP, the appendectomy group was determined as patients aged 20--84 years undergoing appendectomy from 1998 to 2013 (the International Classification of Diseases \[ICD\] 9^th^ Revision, ICD-9 procedure codes 47.0 and 47.1). We identified a study group of 15917 patients who underwent appendectomy between 1998 and 2013. We excluded 2975 persons aged \<18 or \>100 years, 1538 persons with a history of DM history before the index date, 201 patients with any antidiabetic agent history before the index date, eight patients who underwent bariatric surgery, and 241 patients who did not survive or were followed up for \< 30 days. The remaining 10954 patients were included in the study as the appendectomy group. The index year was determined as the year the appendectomy was performed. We established a random frequency-matched study cohort for assessing the association between appendectomy and DM. For each identified appendectomy patient, four control groups were frequency matched by age, sex, and index year. A total of 10954 appendectomy patients and 43815 controls were included in the study cohort ([Fig 1](#pone.0205502.g001){ref-type="fig"}). We also performed a propensity score-matched sensitivity analysis to ensure the reliability of our results. Propensity scores were calculated using multivariate logistic regression to predict the probability of DM occurrence to balance the covariate distribution in the appendectomy and control groups. Based on the propensity score, 1:4 propensity score matching was performed in the sensitivity analysis.

![Flow chart of the study subjects illustrating how we analyzed a cohort of 10954 patients who underwent appendectomy between 1998 and 2013 based on Taiwan National Health Insurance Program data.\
A comparison cohort of 43815 persons without appendectomy was randomly selected and frequency matched by sex, age, comorbidities, and index year. We observed the subsequent development of diabetes in both cohorts.](pone.0205502.g001){#pone.0205502.g001}

All comorbidities were diagnosed with ICD-9 codes. The following comorbidities potentially related to DM included: hypertension (ICD-9 401--405), hyperlipidemia (ICD-9 272), gout (ICD-9 274), polycystic ovaries (ICD-9 256.4), cerebrovascular disease (ICD-9 430--438), renal disease (ICD-9 580--589), ischemic heart disease (CAD; ICD-9 410--414), chronic obstructive pulmonary disease (COPD; ICD-9 416.8, 416.9, 490--505, 506.4, 508.1, and 508), gestational diabetes (GDM) (ICD-9 648.0, 648.8), depression (ICD-9 296.2, 296.3, 300.4, and 311), obesity (ICD-9 278, 783.1, and V77.8), chronic pancreatitis (ICD-9 577.1), hepatitis B infection (HBV; ICD-9 070.20, 070.21, 070.22, 070.23, 070.30, 070.31, 070.32, 070.33, and V02.61), and hepatitis C infection (HCV; ICD-9 070.41, 070.44, 070.51, 070.54, 070.7, and V02.62).

The major outcome was a new diagnosis of DM (ICD-9 250.0--250.9) based on at least three outpatient diagnoses or one hospital discharge diagnosis during the follow-up period. All study subjects were followed until they were diagnosed with DM at the end of 2013.

Statistics {#sec008}
----------

Demographic and clinical characteristics in the appendectomy and non-appendectomy subjects were presented as proportions and mean ± standard deviation (SD). The standardized differences were used with an absolute value for the standardized difference of \>0.1 considered to indicate important imbalances between the two groups for categorical or continuous matching variables, respectively. The incidence of DM was measured as the event number of DM diagnosed during the follow-up year divided by the total follow-up person-years for each subject.

The Cox proportional hazards regression model was applied to measure the hazard ratio (HR) and 95% confidence interval (CI) for the risk of DM in the appendectomy compared to non-appendectomy groups. Multivariate Cox analysis with cause-specific hazard models was used to estimate adjusted hazard ratios (aHRs) adjusted for confounders for appendectomy and other comorbidities including hypertension, hyperlipidemia, gout, polycystic ovaries, depression, cerebrovascular disease, renal disease, CAD, COPD, GDM, obesity, chronic pancreatitis, HBV infection, HCV infection, medications (statins, atypical antipsychotics, HIV drug and corticosteroids for systemic immunosuppressants) and number of visiting clinics.

Uni- and multivariate survival analyses were performed for the incidence and relative risk of DM. A subgroup analysis was used to distinguish between DM risks in the appendectomy and non-appendectomy groups. We then used propensity score-matched analysis to assess the reliability of our results. Propensity scores were calculated using multivariate logistic regression to predict the probability of DM occurrence. The cumulative incidence curves from cause-specific hazard methods for the appendectomy and control groups were also analyzed.

Results {#sec009}
=======

Of the 15917 patients in the appendectomy group, 10954 patients remained after the exclusion of 2975 patients \<18 or \>100 years of age, 1538 patients with a history of DM, 201 patients with a prescription history of antidiabetic agents, eight patients who underwent bariatric surgery, and 241 patients who did not survive or completed \<30 days of follow-up. There were a total of 43815 persons in the control group.

Comparisons in demographic characteristics are shown in [Table 1](#pone.0205502.t001){ref-type="table"}. The mean ages of the appendectomy and control groups were similar (39.5 years), and each was predominantly composed of males (51.06%). In cohort 1 (random frequency-matched analysis), the appendectomy and control groups were matched by hypertension, hyperlipidemia, gout, polycystic ovaries, depression, GDM, depression, obesity, chronic pancreatitis, HBV and HCV, statins, atypical antipsychotics, HIV drugs, corticosteroids, and immunosuppressants. There was a slight difference in Charlson Comorbidity Index score and number of visiting clinics between the two appendectomy and control groups in cohort 1.

10.1371/journal.pone.0205502.t001

###### Comparisons in demographic characteristics, comorbidities medications and clinical outcomes in subjects with and without appendectomy.

![](pone.0205502.t001){#pone.0205502.t001g}

                                    Cohort1 in Main Result (Randomly Frequency matched Cohort)   Cohort 2 in sensitivity analysis (Propensity score matched Cohort)                                          
  --------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------- ------- --------------- -------------- --------
  Sample size                       43815                                                        10954                                                                        43815           10954          
  Gender                                                                                                                                                                                                     
     F                              21443(48.94%)                                                5361(48.94%)                                                         0.000   21252(48.5%)    5361(48.94%)   0.009
     M                              22372(51.06%)                                                5593(51.06%)                                                         0.000   22564(51.5%)    5593(51.06%)   0.009
  Age stratified                                                                                                                                                                                             
     \<20                           2270(5.18%)                                                  635(5.8%)                                                            0.027   2596(5.92%)     635(5.8%)      0.0054
     20--39                         22216(50.7%)                                                 5528(50.47%)                                                         0.005   22438(51.21%)   5528(50.47%)   0.0149
     40--59                         13818(31.54%)                                                3401(31.05%)                                                         0.011   13644(31.14%)   3401(31.05%)   0.0020
     60--79                         4896(11.17%)                                                 1233(11.26%)                                                         0.003   4537(10.35%)    1233(11.26%)   0.0290
     \> = 80                        615(1.4%)                                                    157(1.43%)                                                           0.003   601(1.37%)      157(1.43%)     0.0052
  Age, years                        39.58±15.7                                                   39.5±15.76                                                           0.005   39.08±15.55     39.5±15.76     0.038
  Monthly income, NTD                                                                                                                                                                                        
     \<15840                        19924(45.47%)                                                5182(47.31%)                                                         0.037   20719(47.29%)   5182(47.31%)   0.000
     15840−25000                    13792(31.48%)                                                3561(32.51%)                                                         0.022   14107(32.2%)    3561(32.51%)   0.007
     ≥25000                         10099(23.05%)                                                2211(20.18%)                                                         0.070   8990(20.52%)    2211(20.18%)   0.008
  Number of visiting clinic         15.24±13.75                                                  16.97±14.85                                                          0.165   16.85±14.78     16.97±14.85    0.012
  Charlson's comorbidity index                                                                                                                                                                               
     0                              32080(73.22%)                                                6788(61.97%)                                                         0.242   27272(62.24%)   6788(61.97%)   0.006
     1--2                           9937(22.68%)                                                 3331(30.41%)                                                         0.176   13479(30.76%)   3331(30.41%)   0.008
     ≥3                             1798(4.1%)                                                   835(7.62%)                                                           0.150   3065(7%)        835(7.62%)     0.024
  Comorbidity at baseline                                                                                                                                                                                    
     Hypertension                   3462(7.9%)                                                   1077(9.83%)                                                          0.068   3896(8.89%)     1077(9.83%)    0.032
     Hyperlipidemia                 1313(3%)                                                     442(4.04%)                                                           0.056   1355(3.09%)     442(4.04%)     0.051
     Gout                           938(2.14%)                                                   323(2.95%)                                                           0.051   1088(2.48%)     323(2.95%)     0.029
     Polycystic ovaries             104(0.24%)                                                   35(0.32%)                                                            0.016   114(0.26%)      35(0.32%)      0.011
     Gestational diabetes           29(0.07%)                                                    19(0.17%)                                                            0.031   47(0.11%)       19(0.17%)      0.018
     Depression                     440(1%)                                                      143(1.31%)                                                           0.028   489(1.12%)      143(1.31%)     0.017
     Obesity                        114(0.26%)                                                   40(0.37%)                                                            0.019   101(0.23%)      40(0.37%)      0.025
     Chronic pancreatitis           19(0.04%)                                                    11(0.1%)                                                             0.021   31(0.07%)       11(0.1%)       0.010
     Hepatitis B infection          429(0.98%)                                                   189(1.73%)                                                           0.065   693(1.58%)      189(1.73%)     0.011
     Hepatitis C infection          138(0.31%)                                                   45(0.41%)                                                            0.016   135(0.31%)      45(0.41%)      0.017
  Medication at baseline                                                                                                                                                                                     
     Statins                        559(1.28%)                                                   196(1.79%)                                                           0.042   649(1.48%)      196(1.79%)     0.024
     Atypical Antipsychotics        39(0.09%)                                                    9(0.08%)                                                             0.002   20(0.05%)       9(0.08%)       0.014
     HIV-drug                       20(0.05%)                                                    10(0.09%)                                                            0.017   36(0.08%)       10(0.09%)      0.003
     Corticosteroids for systemic   338(0.77%)                                                   189(1.73%)                                                           0.086   648(1.48%)      189(1.73%)     0.020
     Immunosuppressants             69(0.16%)                                                    22(0.2%)                                                             0.009   70(0.16%)       22(0.2%)       0.010
  Propensity score                  2.92±1.4                                                     3.33±1.41                                                            0.409   0.02±0.01       0.02±0.01      0.000
  Outcome                                                                                                                                                                                                    
     DM                             3027(6.91%)                                                  811(7.4%)                                                            0.019   2819(6.43%)     811(7.4%)      0.0382
     death                          2660(6.07%)                                                  705(6.44%)                                                           0.015   2560(5.84%)     705(6.44%)     0.0247

^a^ StD, standardized difference of greater than 0.1 is considered important imbalance.

To assess the reliability of cohort 1, a propensity score-matched sensitivity analysis (cohort 2) was conducted, and it showed that the appendectomy and control groups had equal distributions of all demographic characteristics. Overall, 7.4% (n = 811) of patients with appendectomy developed type 2 DM versus 6.91% (n = 3027) of persons without appendectomy in cohort 1. Similar results were shown in cohort 2. Using this data mining strategy, we were able to examine the correlation between appendectomy and the development of type 2 DM. As shown in [Table 2](#pone.0205502.t002){ref-type="table"}, we found the overall incidence of type 2 DM in the appendectomy patients was 7.9% higher than that in the control group, although the difference was not statistically significant (P = 0.06). The incidence of type 2 DM in the appendectomy patients \< 30 years of age was 1.453-fold greater than that in the control group (95% CI, 1.093--1.933). The multivariable regression analysis revealed that the adjusted HR of type 2 DM was 1.347 for the appendectomy patients \< 30 years (95% CI, 1.009--1.798) compared to controls. Age affected the association between appendectomy and type 2 DM (P~interaction~ = 0.002), whereas sex did not (P~interaction~ = 0.88).

10.1371/journal.pone.0205502.t002

###### Incidence and hazard ratios of diabetes mellitus for appendectomy patients compared with non-appendectomy cohort by demographic characteristics and comorbidities.

![](pone.0205502.t002){#pone.0205502.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables      Subjects with non-appendectomy   Subjects with appendectomy   Appendectomy vs.\          P~interaction~                                                                                                                       
                                                                               Non- appendectomy cohort                                                                                                                                        
  -------------- -------------------------------- ---------------------------- -------------------------- ----------------- ---------- -------- -------------- ----------------- ------------------- ---------- ------------------- ---------- -----------
  All patients   43815                            3027                         340573.93                  8.89\             10954      811      83432.67       9.72\             1.091\              0.03       1.079\              0.06       
                                                                                                          (8.57,9.2)                                           (9.05,10.39)      (1.01,1.179)                   (0.997,1.168)                  

  Gender                                                                                                                                                                                                                                       0.88

    Male         22372                            1657                         170069.30                  9.74\             5593       445      41937.96       10.61\            1.091\              0.10       1.058\              0.34       
                                                                                                          (9.27,10.21)                                         (9.63,11.6)       (0.983,1.211)                  (0.939,1.192)                  

    Female       21443                            1370                         170504.63                  8.03\             5361       366      41494.71       8.82\             1.092\              0.13       1.072\              0.20       
                                                                                                          (7.61,8.46)                                          (7.92,9.72)       (0.973,1.225)                  (0.964,1.192)                  

  Age, years                                                                                                                                                                                                                                   **0.002**

  **  \<30**     **14041**                        **179**                      **119669.38**              **1.5**\          **3564**   **64**   **29876.48**   **2.14**\         **1.453**\          **0.01**   **1.347**\          **0.04**   
                                                                                                          **(1.28,1.71)**                                      **(1.62,2.67)**   **(1.093,1.933)**              **(1.009,1.798)**              

    30--40       10445                            428                          83434.68                   5.13\             2599       127      20565.12       6.18\             1.223\              0.05       1.095\              0.39       
                                                                                                          (4.64,5.62)                                          (5.1,7.25)        (1.004,1.491)                  (0.892,1.344)                  

    40--50       8587                             785                          66837.74                   11.74\            2114       227      15941.37       14.24\            1.197\              0.02       1.125\              0.12       
                                                                                                          (10.92,12.57)                                        (12.39,16.09)     (1.033,1.386)                  (0.969,1.306)                  

    \> = 50      10742                            1635                         70632.14                   23.15\            2677       393      17049.69       23.05\            0.981\              0.73       0.971\              0.60       
                                                                                                          (22.03,24.27)                                        (20.77,25.33)     (0.879,1.094)                  (0.868,1.085)                  

  Comorbidity                                                                                                                                                                                                                                  0.51

  0              38371                            2183                         308095.21                  7.09\             9173       540      72570.45       7.44\             1.05\               0.31       1.089\              0.08       
                                                                                                          (6.79,7.38)                                          (6.81,8.07)       (0.956,1.154)                  (0.989,1.2)                    

  \> = 1         5444                             844                          32478.72                   25.99\            1781       271      10862.21       24.95\            0.966\              0.62       0.995\              0.94       
                                                                                                          (24.23,27.74)                                        (21.98,27.92)     (0.844,1.106)                  (0.868,1.14)                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^PY, person-years.

^‡^Incidence rate, per 1000 person-years.

^§^Multivariate analysis including age, gender, monthly income, Charlson's comorbidity index, comorbidities (Hypertension, Hyperlipidemia, Gout, Polycystic ovaries, Gestational diabetes, Depression, Obesity, Chronic pancreatitis, Hepatitis B infection and Hepatitis C infection) and medications (Statins, Atypical Antipsychotics, HIV-drug, Corticosteroids for systemic, Immunosuppressants), where death were regarded as competing risks.

cHR: crude hazard ratio; aHR: adjusted hazard ratio; CI: confidence interval.

The incidence of type 2 DM stratified by age is shown in [Table 3](#pone.0205502.t003){ref-type="table"}. Here we used the propensity score-based analysis to confirm the hazard ratio of type 2 DM among patients \< 30 years of age. The multivariate regression analysis revealed that the aHR of type 2 DM was 2.45 in the appendectomy patients \< 20 years (95% CI, 1.039--5.776) compared to controls. The propensity score-matching analysis revealed that the aHR of type 2 DM in the appendectomy patients \< 20 years was 2.525 (95% CI, 1.116--5.695) compared to controls. The propensity score-based analysis revealed that the aHR of type 2 DM in the appendectomy patients \< 30 years was 1.36 (95% CI, 1.02--1.813) compared to controls.

10.1371/journal.pone.0205502.t003

###### Hazard ratio of incident diabetes mellitus stratified by age.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stratify age   aHR[^a^](#t003fn001){ref-type="table-fn"}\   p-value[^‡^](#t003fn004){ref-type="table-fn"}   aHR[^b^](#t003fn002){ref-type="table-fn"}\   p-value[^‡^](#t003fn004){ref-type="table-fn"}   aHR[^c^](#t003fn003){ref-type="table-fn"}\   p-value[^‡^](#t003fn004){ref-type="table-fn"}
                 (95% CI)                                                                                     (95% CI)                                                                                     (95% CI)                                     
  -------------- -------------------------------------------- ----------------------------------------------- -------------------------------------------- ----------------------------------------------- -------------------------------------------- -----------------------------------------------
  \<20           2.45(1.039,5.776)                            0.041                                           2.52(1.116,5.695)                            0.026                                           2.449(1.085,5.528)                           0.031

  \<30           **1.347(1.009,1.798)**                       **0.043**                                       1.36(1.02,1.813)                             0.036                                           1.369(1.027,1.824)                           0.032

  20--30         1.239(0.907,1.691)                           0.178                                           1.26(0.924,1.717)                            0.144                                           1.268(0.931,1.727)                           0.132

  30--40         1.071(0.875,1.31)                            0.509                                           1.144(0.937,1.397)                           0.188                                           1.147(0.939,1.401)                           0.178
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted for all variables listed in [Table 1](#pone.0205502.t001){ref-type="table"}.

^b^Adjusted for propensity score.

^c^Adjusted for strata by quintiles based on propensity scores.

^‡^All analyses incorporated in regard to death as competing risks.

Moreover, the cumulative incidences are shown in [Fig 2](#pone.0205502.g002){ref-type="fig"}. The adjusted HR of type 2 DM in all patients with appendectomy was 1.079 (95% CI, 1.041--1.839), that in patients \> 30 years of age with appendectomy was 1.002 (95% CI, 0.92--1.09), and that in patients \< 30 years of age with appendectomy was 1.36 (95% CI, 1.02--1.813) compared to controls. The incidence of type 2 DM stratified by follow-up period post-appendectomy is shown in [Table 4](#pone.0205502.t004){ref-type="table"}. The incidence of type 2 DM within 3 years post-appendectomy follow-up was higher in the appendectomy patients with an HR of 2.017 (P = 0.03). In contrast, the incidence of type 2 DM \> 10 years post-appendectomy follow-up was lower in the appendectomy group with an HR of 1.442 (P = 0.223).

![Cumulative incidence of diabetes mellitus (DM) between the appendectomy and comparison cohorts comparing the cumulative incidence of DM between the appendectomy and comparison cohorts among the overall patients and those patients younger or older than 30 years of age.](pone.0205502.g002){#pone.0205502.g002}

10.1371/journal.pone.0205502.t004

###### Hazard ratio of incident diabetes mellitus in patient at aged\<30 year during post appendectomy follow-up.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  post appendectomy follow time (year)   aHR[^a^](#t004fn001){ref-type="table-fn"}\   p-value[^‡^](#t004fn004){ref-type="table-fn"}   aHR[^b^](#t004fn002){ref-type="table-fn"}\   p-value[^‡^](#t004fn004){ref-type="table-fn"}   aHR[^c^](#t004fn003){ref-type="table-fn"}\   p-value[^‡^](#t004fn004){ref-type="table-fn"}
                                         (95% CI)                                                                                     (95% CI)                                                                                     (95% CI)                                     
  -------------------------------------- -------------------------------------------- ----------------------------------------------- -------------------------------------------- ----------------------------------------------- -------------------------------------------- -----------------------------------------------
  **\<3**                                **2.017(1.07,3.802)**                        **0.03**                                        **1.946(1.048,3.612)**                       **0.035**                                       **1.951(1.049,3.629)**                       **0.035**

  **3--7**                               **1.764(1.052,2.957)**                       **0.031**                                       **1.861(1.123,3.084)**                       **0.016**                                       **1.786(1.076,2.962)**                       **0.025**

  \<7                                    1.705(1.146,2.538)                           0.009                                           1.732(1.17,2.563)                            0.006                                           1.684(1.138,2.493)                           0.009

  7--10                                  1.232(0.659,2.303)                           0.513                                           1.223(0.668,2.24)                            0.514                                           1.242(0.679,2.271)                           0.482

  \> = 10                                1.442(0.8,2.599)                             0.223                                           1.382(0.771,2.478)                           0.278                                           1.42(0.792,2.547)                            0.239
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted for all variables listed in [Table 1](#pone.0205502.t001){ref-type="table"}.

^b^Adjusted for propensity score.

^c^Adjusted for strata by quintiles based on propensity scores.

^‡^All analyses incorporated in regard to death as competing risks.

Discussion {#sec010}
==========

In this large retrospective population-based cohort study, we found no statistically significant association between appendectomy and type 2 DM in the overall population (aHR, 1.079; 95% CI, 0.997--1.168). However, appendectomy increased the risk of type 2 DM among patients \< 20 years (aHR, 2.45; 95% CI, 1.039--5.776) and those \<30 years (aHR, 1.347; 95% CI, 1.009--1.798). In the random frequency-matched cohort, all confounding factors except Charlson Comorbidity Index score and number of visiting clinics were equally distributed in the appendectomy and control groups. To reduce selection bias, a multivariate regression analysis was conducted of a propensity score-matched cohort, which revealed that the adjusted HR of type 2 DM in the appendectomy patients \< 20 years and those \< 30 years were 2.52 (95% CI, 1.116--5.695) and 1.36 (95% CI, 1.02--1.813) compared to controls. Since the number of appendectomy patients \< 20 years of age was limited, we may have overestimated the impact of age on appendectomy and the development of type 2 DM. Therefore, we concluded that appendectomy prior to 30 years of age is an independent risk factor for the development of type 2 DM.

Apart from significant results in the age subgroup analyses confirmed by the different statistical methods, our results were adjusted by many confounding factors, including hypertension, hyperlipidemia, gout, polycystic ovaries, depression, GDM, depression, obesity, chronic pancreatitis, HBV, HCV, statins, atypical antipsychotics, HIV drugs, corticosteroids, and immunosuppressants. This implies that age indeed had a profound effect on the association between appendectomy and type 2 DM. On the other hand, we found that sex did not influence the association between appendectomy and type 2 DM (P~interaction~ = 0.88). The aHR of type 2 DM incidence in the male appendectomy group was 1.058 (P = 0.34), while that in the female appendectomy group was 1.072 (P = 0.20) compared to controls. Furthermore, the major outcome was a new diagnosis of DM (ICD-9 250.0--250.9), which included type 1 and 2 DM. Because patients with a history of DM before the index year and subjects \< 18 years were excluded, we believe that most of newly diagnosed DM patients after appendectomy have type 2 DM.

Appendicitis is one of the most common acute abdominal diagnoses and mainly results from bacterial infection rather than obstructions within the organ \[[@pone.0205502.ref022]\]. Appendicitis is a clinical emergency for which surgery remains the gold standard of treatment. Similar to our results, appendectomy is associated with various human diseases \[[@pone.0205502.ref016]--[@pone.0205502.ref021]\]; however, the mechanism of their associations is largely unknown. Some possible explanations might address their correlations. First, the appendix is considered a safe house to shelter the commensal intestinal flora through biofilm formation. Second, the appendix is considered part of the immune system because of its abundant gut-associated lymphoid tissue. As a result, appendectomy and prophylactic antibiotics given before appendectomy surgery may disrupt gut microbiota configurations, subsequently supporting diabetes development. Interestingly, several population-based studies from Taiwan were conducted based on the National Health Insurance Research Database (NHIRD) \[[@pone.0205502.ref016], [@pone.0205502.ref018]--[@pone.0205502.ref020]\]. The NHIRD provided the opportunity to investigate the associated with subsequent disease development and appendectomy in real-world settings in a large population sample in Taiwan and can help accumulate evidence for the creation of appropriate surgical interventions to remove the appendix since it might cause long-term health effects.

A recent study revealed that the human appendix accommodates a wealth of microbiota different from other niches and shows substantial diversity \[[@pone.0205502.ref023]\]. Another study suggested that appendiceal dysbiosis appears in insulin resistance morbidly obese (IR-MO) patients, with a reduction of butyrate-producing bacteria that are necessary to maintain gut integrity together with an increase in mucin-degrading bacteria and opportunistic pathogens \[[@pone.0205502.ref024]\]. Meadows identified that *Firmicutes* are associated with weight gain and insulin resistance because they supply extra energy \[[@pone.0205502.ref025]\]. Verdam et al. described that an increase in *Firmicutes* and a decrease in *Bacteriodetes* is linked to the presence of obesity and inflammation \[[@pone.0205502.ref026]\]. Indeed, the appendiceal microbiota have been recognized as an innovate actor capable of modulating the host metabolism through building the appendiceal immune function \[[@pone.0205502.ref024]\].

Most importantly, our study showed that appendectomy increases the risk of type 2 DM, particularly when performed in patients before middle age. We believe that dysbiosis or imbalance of the enteric microbiota may bolster chronic inflammation through intestinal barrier breakdown, microbiota outgrowth, and translocation of the microbiota. Moreover, immunity may weaken with age, thereby lessening inflammation. This might address the possibility of the impact of age on appendectomy to the emergence of type 2 DM. Furthermore, other risk factors may attenuate the effect of appendectomy on the development of diabetes after middle age. Appendectomy appeared to be associated with the risk of diabetes development approximately 3--7 years later. We think that changes in the gut microbiota composition could be prominent at the early stage post-appendectomy due to bacterial infection, surgery, and antibiotic use. However, dysbiosis of the enteric microbiota could be recovered by a degree, so animal studies should be performed to clarify the association between appendectomy and type 2 DM.

Study limitations {#sec011}
-----------------

There are some limitations in our study. First, lifestyle data regarding dietary habits, exercise, smoking, socioeconomic status, and hereditary background were not available in this retrospective cohort study. Second, all comorbidities were diagnosed using ICD-9 codes, the accuracy of which should be discussed. Third, we did not separate perforated appendicitis from non-perforated appendicitis or distinguish between laparoscopic appendectomy and open appendectomy. Fourth, despite of our thorough study design and adjustment for confounding factors, some selection bias may have resulted from the retrospective nature of this study.

Conclusions {#sec012}
===========

In conclusion, appendectomy performed in patients \< 30 years is associated with the risk of type 2 DM independent of hypertension, hyperlipidemia, gout, polycystic ovaries, depression, GDM, depression, obesity, chronic pancreatitis, HBV, HCV, statins, atypical antipsychotics, HIV drugs, corticosteroids, and immunosuppressants. The results of this study implicate that the appendix protects against type 2 DM development before middle age. Further studies should be performed to clarify the role of appendectomy in the development of diabetes.
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